Sun Pharmaceutical Industries Ltd. has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma’s specialty focus areas.
Under the terms of the license agreement, Sun Pharma gets exclusive global license for the said patents and any other future patents covered in the agreement. Sun Pharma will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totalling up to Rs. 2.40-bn, plus royalties on net sales from commercialisation of the products developed using these patents. Sun Pharma will be responsible for development, regulatory filings, manufacturing and commercialisation of these potential products.
“This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline. CSIR-IICT is well-known for its high quality research and we are proud to be associated with them. We are making earnest efforts to bring innovations from Indian research institutes to the market to address the unmet needs of patients globally. Our collaboration with CSIR-IICT is a step in this direction,” Mr. Dilip Shanghvi, Managing Director, Sun Pharma said.
The agreement is expected to facilitate addition of pre-clinical candidates to Sun Pharma’s global specialty pipeline. A successful clinical development of these potential compounds may enable Sun Pharma to commercialise pharmaceutical products for various therapeutic indications over the long term.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
The main reasons for the continued fluctuations in the coke market
Coke prices will generally stabilize in 2020
Southern Xinjiang Customs released 188000 tons of imported natural gas
China's total output of various plastic additives in the world
The State Council issues the circular to strengthen the capital management
The total profit of state-owned enterprises is close to 3 trillion yuan